Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of pregabalin can be broken down into several components which progressively intensify proportional to dosage.
Pregabalin's headspace is comparable to a more clear-headed alcohol or benzodiazepine intoxication, although it can take a more dissociative turn at very high dosages.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Initially assessed as having low abuse potential, recreational use has prompted re-evaluation. Euphoric effects can lead to escalating doses above therapeutic ranges, particularly in individuals with current or past substance use disorders. At standard therapeutic doses the risk of addiction is low, but increases with higher doses and prolonged use.
Physical dependence can develop with chronic use, though the FDA determined the dependence profile is quantitatively less severe than benzodiazepines. Withdrawal symptoms after abrupt discontinuation include anxiety, insomnia, sweating, muscle spasms, gastrointestinal disturbances, palpitations, and flu-like symptoms. Even short-term users have reported withdrawal effects. Gradual tapering over at least one week is recommended.
Pregabalin has a relatively wide therapeutic index and margin of safety. Human case reports document survival after single ingestions of 8,400mg and up to 11,500mg with supportive care alone. Overdose is not typically fatal unless combined with other CNS depressants such as opioids, benzodiazepines, or alcohol. Rising fatality rates in surveillance data primarily reflect polysubstance use rather than pregabalin toxicity alone.
| Species | Route | Value |
|---|---|---|
| rodent | oral | >5000 mg/kg |
| rat | IV | >300 mg/kg |
Respiratory depression can occur, particularly when combined with opioids or other CNS depressants, or in individuals with pre-existing lung conditions; the effect is less pronounced than with opioids or benzodiazepines when pregabalin is used alone.
Prolonged use beyond one year has been associated with increased risk of thrombotic events including deep venous thrombosis and pulmonary embolism; heart failure risk does not appear elevated.
Kidney damage is listed among serious side effects; patients with pre-existing renal impairment may accumulate the drug and develop myoclonus due to reduced clearance.
Elevated creatine kinase levels occur commonly; rhabdomyolysis and myositis have been reported rarely, primarily with prolonged high-dose use.
Thrombocytopenia occurs infrequently and neutropenia rarely; these effects are generally identified through routine monitoring rather than clinical symptoms.
Psychotic side effects including hallucinations and confusion occur in a minority of users even at therapeutic doses. Sleep deprivation strongly potentiates this risk, and individuals genetically predisposed to schizophrenia may be more susceptible. Hallucinations are reported in 0.1-1% of users.
Paradoxically, despite being an anticonvulsant, pregabalin may induce or increase seizure risk at recreational doses exceeding 600mg. There is little evidence of concern at medical doses. The drug may aggravate myoclonus and myoclonic seizures in susceptible populations. Risk factors include low sodium, sleep deprivation, and intensive physical activity.
Pregabalin emerged from research conducted at Northwestern University in Evanston, Illinois. In 1988, medicinal chemist Richard Silverman enlisted the help of Dr. Ryszard Andruszkiewicz, a visiting scholar from the Technical University of Gdańsk, to synthesize a series of 3-alkyl-GABA and…
Listed as a Schedule 4 prescription-only medicine under the Poisons Standard. Legal to possess only with a valid prescription from a registered medical practitioner.
Classified as a controlled substance as of June 1, 2023, due to concerns about misuse and dependence potential.
Listed in prescription schedule B alongside benzodiazepines and opioid painkillers. Rescheduled from the less restrictive schedule C due to documented recreational use, tolerance development, and addiction concerns.
Listed as an 'Abgabekategorie B' pharmaceutical under Swiss regulations, meaning dispensing requires a valid medical prescription.
Controlled under the Misuse of Drugs Act 1971 as a Class C drug, effective April 1, 2019. Also listed as Schedule 2 under the Misuse of Drugs Regulations. Possession without a valid prescription is a criminal offense.
Regulated as a prescription-only medication. Available through licensed pharmacies with a valid prescription from a healthcare provider.
Regulated as a prescription medicine according to Anlage 1 of the Arzneimittelverschreibungsverordnung (AMVV). Not scheduled as a controlled narcotic but requires medical prescription for legal possession and dispensing.
Classified as a controlled substance under Schedule V since July 24, 2018. Requires prescription for legal possession and is subject to stricter monitoring than standard prescription medications.
Regulated under the 'green prescription' system, which applies to medications with abuse potential. Illegal to sell or possess without a valid prescription.
Classified under Schedule V of the Controlled Substances Act, indicating low potential for abuse relative to Schedule IV substances such as benzodiazepines. Illegal to sell without a DEA license and illegal to possess without a valid prescription.
27 sources cited
